The weekly litigation news digest is live. Subscribe now

Methods For Treating Diseases Using Isoindoline Compounds - EP3320902

The patent EP3320902 was granted to Amgen Europe on Feb 17, 2021. The application was originally filed on Mar 2, 2012 under application number EP17208060A. The patent is currently recorded with a legal status of "Revoked".

EP3320902

AMGEN EUROPE
Application Number
EP17208060A
Filing Date
Mar 2, 2012
Status
Revoked
Jul 22, 2022
Publication Date
Feb 17, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSNov 16, 2021D YOUNGADMISSIBLE

Patent Citations (19) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS3536809
DESCRIPTIONUS3598123
DESCRIPTIONUS3845770
DESCRIPTIONUS3916899
DESCRIPTIONUS4008719
DESCRIPTIONUS5059595
DESCRIPTIONUS5073543
DESCRIPTIONUS5120548
DESCRIPTIONUS5354556
DESCRIPTIONUS5591767
DESCRIPTIONUS5639476
DESCRIPTIONUS5674533
DESCRIPTIONUS5733566
DESCRIPTIONUS6020358
DESCRIPTIONUS6667316
DESCRIPTIONUS6962940
SEARCHUS2008234359
SEARCHUS2010280079
SEARCHWO2008013791

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents